spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Rentschler Biotechnologie GmbH Announces Transition into a European Corporation Called Rentschler Biopharma SE

Rentschler Biotechnologie GmbH

Rentschler Biotechnologie GmbH announced that the Company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on October 1, 2017

Laupheim, Germany, October 4, 2017 – Rentschler Biotechnologie GmbH, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that the Company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on October 1, 2017. The Company is operating as Rentschler Biopharma SE with immediate effect. There will be no operational changes for clients or employees of the family-owned company due to the transition.

“With our transition to Rentschler Biopharma SE, we emphasize our long-term international corporate identity, while the core business remains unaffected. In future, this legal form of company strengthens our position as a full-service CDMO and ensures our place as a leader in this industry,” commented Prof. Dr. Nikolaus F. Rentschler, Owner of Rentschler Biopharma SE. “Our proven service offering along the entire value chain – from bioprocess development through biomanufacturing to fill and finish of biopharmaceuticals – remains unchanged. This also applies to our company sites and manufacturing facilities as well as the existing client relations and importantly their contact persons.”

Over the recent years, Rentschler Biopharma has grown considerably and invested constantly in facilities so that capacities have more than doubled. With the expansion of our facilities, a continually growing number of employees has also been added to the Company. About 200 employees have been recruited in all business segments during the past year and a half. In the current fiscal year, over 120 additional positions are to be filled.

Rentschler will present itself as Rentschler Biopharma SE for the first time at the 23rd Annual International Partnering Conference BIO-Europe at booth 42/43. The conference takes place November 6-8, 2017 at Messe Berlin.

The term “European Corporation”, from the Latin: Societas Europaea (SE), is a legal form for incorporated companies in the European Union and the European Economic Area and enables the foundation of companies according to standardized legal principles.

About Rentschler Biopharma SE
Rentschler Biopharma SE, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO) for bioprocess development and manufacturing of biopharmaceuticals as well as for related consulting activities in terms of project management and regulatory support. The Company's clients include innovative biotech companies and major pharmaceutical companies around the world. Many years of experience and excellence in finding solutions as well as certified quality management and advanced technologies ensure Rentschler Biopharma's high quality standards. Rentschler Biopharma is a family-owned company employing approximately 750 people. For further information, please visit www.rentschler-biopharma.com.

Contact
Rentschler Biopharma SE
Dr. Marion Schrader
Senior Director Company Communication and Public Relations marion.schrader@rentschler-biopharma.com
phone +49 7392 701-0
email info@rentschler.de
web www.rentschler.de
email Erwin-Rentschler-Str. 21, 88471 Laupheim
 
Print this page
Send to a friend
   
spacer
News and Press Releases

HATRIC-based identification of receptors for orphan ligands (small molecules)

HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!
More info >>


White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

Industry Events

HPLC 2018

29 July - 2 August 2018, Washington Marriott Wardman Park, Washington, DC, USA

Are you interested in mass spectrometry, chromatography, or electrophoresis? Are you solving complex analytical problems? Are you looking for a conference with strong scientific content, a robust program, presentations by world renowned experts, lectures by young scientists, courses offering great training opportunities, tutorials, panel discussions, vendor technical workshops, best poster competition, and a major exposition showcasing new product launches and innovative products? Mark your calendar to attend HPLC 2018 Washington, DC, the largest, most recognized international conference in the world devoted to advances in separation technologies!
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement